14. Pierre Fenaux, Ghulam J Mufti,Eva Hellstrom-Lindberh,et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.Lancet Oncol,2009,10: 223-232 15.Lyons RM,Cosgriff TM...
Patients and caregivers place high importance on treatment options that provide better perceived QoL over treatments that provide a moderate extension to life expectancy and require hospitalisation. This study highlights the need to consider patient perceptions of QoL and the importance of understanding ...
Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol, 2009, 27:3842-3848. Blum W. How much? How frequent? How...
prognostic score, which is based on some of the features of your disease. This can help determine if you have lower-risk MDS, which may mean that you can live for years before you need treatment, or higher-risk MDS, which may mean a shorter life expectancy and more aggressive treatment....
International expert panel has confirmed the indication of HCT in HR-MDS and in LR-MDS when they have or acquire specific poor prog- nostic features, including genetic alterations, failure to respond to usual treatment, life-threat- 74 Myelodysplastic Neoplasms/Syndromes (MDS) 671 ening ...
However, this study emphasized that alloreactivity is the main therapeutic principle that contributes to exceeding tolerable conditioning intensity in MDS treatment. 2.2. Melphalan comparison with busulfan To increase the likelihood of sustainable remission, melphalan was introduced to RIC for the treatment...
Matrix metalloproteinase 1(MMP1), which was downregulated in MDS-MSCs, was identified as an inhibitory factor of MDS cell proliferation, given that treatment with an MMP1 inhibitor or knock-down of MMP1 in normal MSCs resulted in increased MDS cell proliferation. Further investigations indicated ...
with the IPSS-M, but this needs to be confirmed. Especially LR-MDS are very heterogeneous with expected median survival between 3 and 10 years. As a result, intensive treatment strategies are predominantly applied in patients with HR-MDS, whereas LR-MDS tend to be treated conservatively (Robin...
import interpreted in regards to treatment, because acute myeloid the revised IPSS (table 6),8 which also uses cytog ic leukaemia is generally considered for chemotherapy and abnormalities, cytopenias, and blast count for scoring higher-risk myelodys stic syndromes for hypo- but with new ...
Approximately one-third of patients with myelodysplastic syndrome (MDS) receiving allogeneic hematopoietic stem cell transplantation (HSCT) are cured by this treatment. Treatment failure may be due to transplant complications or relapse. To identify predictive factors for transplantation outcome, we studied...